Your browser doesn't support javascript.
loading
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman, Reid W; Redd, Robert; Jeter, Erin; Wong, Jeff L; McHugh, Kristin; Reynolds, Carol; Nazzaro, Matthew; Varden, Aine; Brown, Jennifer R; Crombie, Jennifer L; Davids, Matthew S; Fisher, David C; Jacobsen, Eric; Jacobson, Caron A; Kim, Austin I; LaCasce, Ann S; Ng, Samuel Y; Odejide, Oreofe O; Parry, Erin M; Dahi, Parastoo B; Nieto, Yago; Joyce, Robin M; Chen, Yi-Bin; Herrera, Alex F; Armand, Philippe; Ritz, Jerome.
Afiliación
  • Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: Reid_merryman@dfci.harvard.edu.
  • Redd R; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jeter E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wong JL; Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, New York; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
  • McHugh K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Reynolds C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Nazzaro M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Varden A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jacobsen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Joyce RM; Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Chen YB; Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, Massachusetts.
  • Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
  • Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Transplant Cell Ther ; 28(1): 32.e1-32.e10, 2022 01.
Article en En | MEDLINE | ID: mdl-34670169
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Trasplante de Células Madre Hematopoyéticas / Reconstitución Inmune Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Trasplante de Células Madre Hematopoyéticas / Reconstitución Inmune Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article